Clinical trials · Michigan
Graft Versus Host Disease clinical trials in Michigan
We’re tracking 12 recruiting graft versus host disease studies with a site in Michigan — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Ann Arbor, MichiganAges 12 years+ - NCT05718791Recruiting
Testing blood markers to predict graft-versus-host disease
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Detroit, MichiganAges 18–80 - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Ann Arbor, MichiganAges 2 years+ - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Detroit, MichiganAges 2 years+ - NCT04886726RecruitingPhase 1
New medicine to prevent graft-versus-host disease after transplant
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Detroit, MichiganAges 18–70 - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Ann Arbor, MichiganAges 3 years+ - NCT05919511Recruiting
Questionnaire study for people at risk after stem cell transplant
This observational study follows people who had a stem cell transplant a few months ago to better understand risk for chronic graft-versus-host disease. You won’t get a study treatment; instead, you’ll complete questionnaires over time, and the study team looks at your symptoms and experiences.
Grand Rapids, MichiganAges 18 years+ - NCT05922761RecruitingPhase 2
Belumosudil for lung scar prevention or treatment after transplant
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Ann Arbor, MichiganAges 18 years+ - NCT06615050RecruitingPhase 3
Comparing two drug combinations for stem cell transplant
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
Detroit, MichiganAges 18 years+ - NCT06619561RecruitingPhase 2
Testing vimseltinib for chronic graft versus host disease
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
Detroit, MichiganAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Detroit, MichiganAges 18–66 - NCT01804686RecruitingPhase 3
Long-term ibrutinib follow-up with or without nivolumab
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
Ann Arbor, MichiganAges 18 years+
Graft Versus Host Disease trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting graft versus host disease studies listed above.
- University of Michigan · 7 studies
- Henry Ford Health · 6 studies
- Wayne State University/Karmanos Cancer Institute · 3 studies
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · 2 studies
- Barbara Ann Karmanos Cancer Institute
- Battle Creek Health Systm
What taking part in a graft versus host disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Graft Versus Host Disease trials in other states
Common questions
- Are there graft versus host disease clinical trials in Michigan?
- Yes. We're currently tracking 12 recruiting graft versus host disease studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a graft versus host disease study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New graft versus host disease studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.